T cell receptor (TCR) gene-modified T cells are a promising immunotherapy but require refinement to improve clinical responses and limit off-target toxicities. A variety of TCR and gene-delivery vector modifications have been developed to enhance introduced TCR expression and limit introduced/endogenous TCR chain mispairing, improving target antigen recognition and minimizing mispairing-induced cross-reactivity. Using our well-characterized HCV1406 TCR, we previously compared the impact of various chain pairing enhancing modifications on TCR expression and cognate antigen recognition. HCV1406 TCR is also natively cross-reactive against naturally occurring altered peptide ligands (APLs), which was shown to be dependent on high TCR surface density.
INTRODUCTION
The use of TCR gene-modified T cells to treat malignancies is a promising immunotherapy, but refinements in their design and implementation are needed to improve clinical outcomes and minimize adverse events. 1 For instance, a variety of clinical trials displayed a range of on-and off-target adverse events. These included toxicities in the eye and inner ear using a gp100-reactive TCR for melanoma 2 ; Abbreviations: APL, altered peptide ligand; CEA, carcinoembryonic antigen; DSB, disulfide bridge; GVHD, graft-versus-host disease; hAB, human AB serum; HCV, hepatitis C virus; LZ, leucine zipper; mC 2, murinized constant region 2 locus; pMHC, peptide-major histocompatability complex; TCR, T cell receptor; WT, wild type inflammatory colitis targeting carcinoembryonic antigen (CEA)-positive colon cancer due to recognition of CEA-expressing normal colon tissue 3 ; neurotoxicity caused by cross-reactivity against MAGE-A12 by a MAGE-A3-reactive TCR 4 ; and cardiogenic shock and death due to unexpected cross-reactivity against titin expression in cardiac tissue by another MAGE-A3-reactive TCR. 5, 6 Another safety concern is the potential for novel self-reactivity caused by mispairing between introduced and endogenous TCR and chains. One study demonstrated novel allo-HLA-reactivity by mixed TCR dimers in vitro, 7 and a mouse model demonstrated graft-versus-host disease (GVHD) in 5 TCR systems. 8 While to date there has been no clinical evidence of GVHD in over 100 patients treated with TCR gene-modified T cells, 9 it remains a possibility.
To help prevent adverse events of TCR mispairing and improve targeted antigen recognition, many groups have used a variety of techniques to alter gene delivery vectors, TCR sequence, or TCR structure to promote efficient transgene translation, augment surface expression, and/or facilitate proper pairing and of introduced TCRs. These strategies include codon optimization of transgenes, 10, 11 addition of cysteine residues in the and constant regions to promote disulfide bridge (DSB) formation, 12 addition of C-terminal leucine zippers (LZs), 13 substituting human constant regions with portions of or the entire mouse constant regions (murinization), [14] [15] [16] [17] [18] or engineering V -V single chain TCRs. [19] [20] [21] Recently, we directly compared the ability of each of the above modifications to augment surface expression and increase reactivity of T cells engineered to express a hepatitis C virus (HCV)-reactive TCR (HCV1406 TCR). We found that LZ and constant region murinization with C 2 modifications induced the greatest increase in properly paired TCR expression and T cell reactivity. 22 We have also shown, however, that this HCV1406 TCR cross-reacts against naturally occurring mutant immune escape variants, 23 and that the surface density of introduced TCRs in gene-modified T cells has a critical impact on the recognition of cognate and altered peptide ligands (APLs). 24 Because we and others have shown that TCR chain pairing enhancing modifications increase surface expression and relative surface density, they could potentially induce recognition of low levels of cognate antigen or cross-reactivity against APLs. In this study, we utilize our well-characterized HCV1406 TCR and APL model to determine if TCR pairing-enhancing strategies impact cross-reactivity against related ligands.
We show in a Jurkat model that the absence of an endogenous TCR alleviates dependence on the CD8 coreceptor for recognition of low-affinity APLs by HCV1406 TCR and induces novel cross-reactivity against a previously unrecognized APL. Interestingly, LZ and C 2 constant region murinization modifications of HCV1406 TCR allowed CD4 + PBL to recognize previously CD8-dependent ligands, CD8 + PBL to novelly recognize an additional APL. These observations have significant implications for the use of such enhanced TCR chain-pairing strategies on the safety in patients, but also might be useful in generating polyclonal reagents where recognition of immune escape variants may be critical for eliminating genetically unstable diseases, including HCV.
MATERIALS AND METHODS

Cells and media
HEK293GP, PG13, T2, Jurkat E6.1, and Jurkat76 cell lines were obtained from the American Type Culture Collection (Rockford, MD).
All medium components were obtained from Corning Life Sciences (Corning, NY), unless otherwise noted. HEK293GP cells were maintained in DMEM supplemented with 10% FBS (Invitrogen Life Technologies, Carlsbad, CA). PG13 cells were maintained in Iscove's DMEM supplemented with 10% FBS. Jurkat E6.1 and Jurkat76 cells were engineered to express CD8 using retroviral vectors as previously described. 23 T2, Jurkat E6.1, and Jurkat76 cells were maintained in RPMI 1640 medium supplemented with 10% FBS. PBMC were purchased as deidentified apheresis products from Key Biologics (Memphis, TN) and isolated using Ficoll-Paque (General Electric Company, Fairfield, CT) density gradient centrifugation. PBMC were stimulated prior to transduction with 50 ng/mL anti-CD3 mAb (Miltenyi Biotec, Bergisch Gladbach, Germany) in AIM-V medium supplemented with 5% human AB serum (hAB; Valley Biomedical, Inc., Winchester, VA), 300 IU/mL IL-2 (Novartis Pharmaceuticals Corporation, East Hanover, NJ), and 100 ng/mL IL-15 (Biological Resources Branch, National Cancer Institute, Bethesda, MD). T cells were maintained in AIM-V medium supplemented with 5% hAB, 300 IU/mL IL-2 and 100 ng/mL IL-15.
Peptides
The generation and rationale for naturally occurring mutant HCV NS3:1406-1415 epitopes has been previously described. 23 Wild type (WT) and variant 1406-1415 peptides as well as tyrosinase:368-376 (used as a negative control) were purchased from Synthetic Biomolecules (San Diego, CA) at 95% purity.
Retroviral transduction
Generation of WT, DSB, LZ, constant region substitution with the murine C and C 2 (mC 2) modified TCR retroviral vectors were previously described. 22 Retroviral supernatants were prepared using stable, high-titer producer PG13 cells expressing WT and pairingmodified TCRs in modified SAMEN retroviral vectors each containing TCR chain linked to chain and a truncated CD34 molecule by a P2A or T2A self-cleaving sequence, respectively. 25 Generation of PG13 retroviral producer cell lines, preparation and collection of retrovirus, and TCR transduction by spinoculation have been described elsewhere. 25 Cultures were enriched for high and uniform transgene expression by positive selection using anti-CD34 mAb-coated immunomagnetic beads (Miltenyi Biotec).
Immunofluorescence
Expression of T cell surface markers was determined by immunofluorescence staining using fluorochrome conjugated mAbs: anti-CD3-APC/Cy, anti-CD4-PE/Cy7, anti-CD8-PerCP/Cy5.5, anti-CD34-PE; Biolegend, San Diego, CA). Expression of Jurkat cell surface markers was determined by immunofluorescence staining using mAb's: anti- 
Cytokine release assays
Peptide-loaded T2 cells were used as stimulators. HCV1406 TCRtransduced Jurkat E6.1, Jurkat76, or PBL-derived normal human T cells were used as effectors. T2 cells were pulsed with 10 g/mL peptide for 2 h. 1 × 10 5 stimulators and 1 × 10 5 effectors were cocultured in 96-well U-bottom tissue-culture plates overnight at 37 • C, 5% CO 2 . 25 10 ng/mL PMA (Sigma-Aldrich, St. Louis, MO) was added to Jurkat E6.1 and Jurkat76 cell cocultures to enhance sensitivity of stimulation. 23 Supernatants were harvested, and the amount of IL-2 or IFN-released by 1 × 10 5 Jurkat or T cells, respectively, was measured by ELISA (Biolegend).
Intracellular IFN-/degranulation bifunctional assay
CD107a expression was used a surrogate marker for lytic func- 
Statistical analysis
Log transforms were taken as needed to symmetrize data prior to statistical analysis. Comparisons of mean cytokine release by Jurkat E6.1 and Jurkat76 cells were performed using 2-sample t tests with unequal variances. To evaluate the differences in T cell reactivity with multiple donors and replicates, linear regressions were fit per cell type (CD4 + total reactivity, CD4 + bifunctional, CD8 + total reactivity, or CD8 + bifunctional) and per peptide condition. Covariates in the models included main effects of donor and main effects of "treatment group" (where groups are WT, DSB, LZ, and mC 2). Wald tests were used for each peptide condition and cell type to test for difference between treatment groups and WT.
Ethics statement
All recombinant DNA and retroviral transduction work was done under approved Loyola University Chicago Institutional Biosafety Committee protocols. Human PBMC used were derived from deidentified apheresis products purchased from commercial sources. Therefore, these studies are not considered Human Subjects Research and did not require Institutional Review Board approval. Together, this Jurkat system serves as a useful tool to evaluate the effects of TCR chain mispairing and TCR pairing-enhancing modifications on APL recognition and CD8 dependence.
RESULTS AND DISCUSSION
Absence of TCR-pairing competition enhances HCV1406 TCR cross-reactivity and can alleviate CD8 dependence
We previously reported that HCV1406 TCR is cross-reactive against a variety of naturally occurring immune escape variant epitopes of HCV NS3. 23 We also demonstrated that recognition of HCV1406 TCR-APL interactions cluster into ranges of TCR-peptidemajor histocompatability complex (pMHC) affinity that tend to dictate CD8 dependence. These affinity ranges are useful to differentially evaluate the effects of TCR chain pairing competition. For our purposes here, APLs cluster into moderate (<100 M) and low (>100 M) affinity, compared to WT TCR-pMHC interaction (17 M). 24 Jurkat E6.1 and Jurkat76 cells were transduced to express the HCV1406 TCR and sorted for high and uniform transgene expression using our CD34 marker (Fig. 1C) . Despite similar transgene expression, tetramer staining suggested TCR-transduced Jurkat76 cells had dramatically higher HCV1406 TCR surface expression than TCR-transduced Jurkat E6.1 cells due to absent chain pairing competition (Fig. 1D) . Reactivity of HCV1406 TCR-transduced Jurkat E6.1 cells recapitulated our previous observations that recognition of WT and moderate affinity mutants V1408L, I1412L, I1412V, and V1408T are recognized by both CD8 + and CD8 − Jurkat E6.1 cells, and recognition of lowaffinity mutants A1409T, I1412N, and 8S/9S/12L/14S is dependent on the expression of the CD8 coreceptor (Fig. 1E) . We have previously shown that the dependence on CD8 is influenced by on both TCR-pMHC structural stabilization as well as lck-recruitment to the TCR/CD3 complex. 24, 28 Surprisingly, CD8 − HCV1406 TCRtransduced Jurkat76 cells secreted significant amounts of IL-2 against low-affinity variants A1409T, I1412N, and 8S/9S/12L/14S, indicating that enhanced TCR pairing can lead to reversal of CD8 dependence or an apparent increase in TCR-pMHC affinity. The differences in IL-2 release between CD8 − and CD8 + Jurkats against moderate affinity APL were also much smaller in the absence of an endogenous TCR. Additionally, the absence of TCR chain pairing competition enhanced the cross-reactivity of HCV1406 TCR as CD8 + Jurkat76 cells recognized 8S/9G/12L (Fig. 1F) . This APL was not recognized in Recently, some investigators have attempted to eliminate the expression of endogenous TCRs using siRNA, designer zinc-finger nucleases, or transcription activator-like effector nucleases to augment expression and pairing rather than modifying the introduced TCR. [30] [31] [32] In light of our observations with HCV1406 TCR, it is imperative that careful measures are taken to evaluate the consequences of absent pairing competition on the requirements for antigen recognition and cross-reactivity in other TCR gene-modified T cells as these strategies become more widespread.
Constant region murinization using C 2 enhances cross-reactivity and alleviates CD8 dependence in TCR-transduced Jurkat E6.1 cells
We have previously compared the impact of various TCR chain pairing enhancing strategies on relative surface expression and T cell reactivity against cognate antigen. 22 Because TCR chain pairing competition has a direct impact on TCR cross-reactivity, we wanted to evaluate if TCR chain pairing enhancing strategies alter the cross-reactivity against naturally occurring APLs. In our previous report, we determined that addition of a constant region DSB, C-terminal LZ, and murinization of TCR constant regions specifically using C 2 (mC 2) had the greatest impact on transgene expression, surface density, and/or reactivity by IFN-release and degranulation. Because these modifications had the greatest effect on surface density, we focused on these modifications. CD8 + and CD8 − Jurkat E6.1 cells were engineered to express WT HCV1406 TCR, DSB, LZ, or mC 2 modifications, and enriched for high and uniform transgene expression using our CD34 marker ( Fig. 2A) .
We previously showed that there is a direct relationship between CD34 + expression and antigen-specific multimer binding by our TCR-transduced cells. 22 Therefore, we know that enhanced tetramer binding demonstrates enhanced surface pairing of the modified TCRs compared to WT (Fig. 2B) . Gated on CD34 + (TCR-transduced) cells, percentages of tetramer-positive cells reflect the relative density of properly paired introduced TCR in cells expressing the TCR transgene. 22 While DSB had modestly improved tetramer binding by CD8 − Jurkat E6.1 cells (9% compared to 5% of WT TCR), LZ and mC 2 modifications facilitated 3-4-fold enhanced tetramer binding compared to WT. Additionally, LZ-and mC 2-modified TCRs dramatically enhanced tetramer binding from 33% (WT) to 51% and 58%, respectively. These data demonstrate that while all groups have relatively similar TCR transgene expression levels (using CD34 as a surrogate marker), modified TCRs augment the relative surface expression of the introduced TCR evaluated by tetramer binding, as previously described. 22 To evaluate the impact of TCR chain pairing enhancing modifications on cross-reactivity and CD8-depedence, TCR-transduced Jurkat (Fig. 2D) . Interestingly, the LZ-modified TCR exhibited lower IL-2 release compared to DSB or mC 2 against all APLs and was comparable to WT TCR against low-affinity APLs. We previously speculated that LZs may interfere with signaling scaffolding at the TCR/CD3 complex 22 and may be responsible for only modest increases in IL-2 release here as well.
Interestingly, none of the modified TCRs recognized 8S/9G/12L
even with CD8 present. This suggests that while mC 2 increases CD8-independent cross-reactivity in Jurkat E6.1 cells, it can promote proper chain pairing, but cannot fully eliminate competition for CD3 or surface expression with the endogenous TCR. An alternative hypothesis is that either TCR modifications or the presence of CD8 may structurally alter the TCR-pMHC interface, inducing novel mechanisms for cross-reactivity or CD8 independence. To evaluate for changes in pMHC interface, we measured fold change in reactivity of TCR-transduced Jurkat E6.1 cells in the absence (Fig. 2E) or presence (Fig. 2F ) of CD8 against a panel of alanine-substituted NS3:1406-1415 peptides. Interestingly, while certain peptide residues are key for antigen recognition (i.e., K1406 and G1411), the pattern of recognition is uniform among all TCRs regardless of the presence of CD8, suggesting that these modifications do not alter the way in which the TCR engages with pMHC. Together, these data suggest that reducing TCR chain mispairing and enhancing relative density of the introduced TCR can impact cross-reactivity and eliminate the requirement for CD8. cell basis. Experiments were performed 3 times using 3 independent PBL donor sources (n = 9). Fig. 3A and B is a representative experiment displaying functional differences between CD4 + and CD8 + T cells, respectively. Tables 1 and 2 summarize averages among the 9 experiments, which are referenced below and were used to test for statistically significant differences among TCRs.
Additions of C-terminal
In CD4 + T cells, the LZ and mC 2 modifications greatly increased the total average number of total percent reactive cells against WT peptide (63.2% and 64.7%, respectively) compared to WT (38.5%) and DSB (42.1%) TCR-transduced T cells ( Fig. 3A; Table 1 ). LZ and mC 2 modifications also elicited significant increases in total percent reactive cells against moderate affinity APL: I1412L (1.4-and 1.6-fold increase, respectively), V1408T (2.0-and 1.8-fold increase), V1408L
(1.4-and 1.6-fold increase), and I1412V (1.5-and 1.9-fold increase) compared to WT TCR-engineered CD4 + T cells. Interestingly, both LZ and mC 2 also facilitated robust IFN-production and degranulation by CD4 + PBL against previously CD8-dependent, low-affinity APL A1409T and I1412N. Modest, but significant, IFN-production and degranulation was also seen against 8S/9S/12L/14S and 8S/9S/12L. Additionally, the LZ and mC 2 modifications often induced a greater proportion of lytic activity in CD4 + T cells, which could be useful in eliciting a more diverse immune response (Fig. 3A) .
DSB, and to a much greater extent LZ and mC 2 modifications, also significantly enhanced IFN-production and degranulation by CD8 + T cells against WT antigen and both moderate and low-affinity APL ( Fig. 3B; Table 2 ). Sixty-five and seventy percent of WT TCRtransduced CD8 + T cells produced IFN-and/or degranulated against WT and moderate affinity APL, which increased to generally over 90% when engineered with LZ-or mC 2-modified TCRs. Additionally, 8S/9G/12L was recognized by CD8 + T cells engineered with It is important to highlight that LZ and mC 2 modifications facilitated CD4 + T cell recognition of previously CD8-dependent APL exhibiting ∼10-fold lower affinity than WT peptide. 24 Because these modifications did not directly alter the TCR-pMHC interface, they may provide an alternative way to facilitate antigen recognition by CD4 + T cells with natively CD8-dependent TCRs without modifying TCR affinity. Although enhancing TCR affinity has generated more avid CD4 + and CD8 + effectors, affinity (as well as target antigen choice) has played a role in facilitating on-and off-target adverse events discussed earlier. [2] [3] [4] [5] [6] Additionally, enhanced TCR-pMHC affinity can cause activation-induced cell death upon antigen encounter, potentially reducing therapeutic efficacy. 33, 34 The ability to modify the TCR without changing its biophysical properties with pMHC may be However, it must be considered how these strategies could impact cross-reactivity and other requirements for recognition including CD8 dependence. While it may offer new CD4 + helper support without modifying the TCR affinity, unintended consequences of enhanced cross-reactivity could be costly for patients. While HCV1406 TCR provides a model to evaluate the effects of enhanced TCR chain pairing on cross-reactivity, it is nevertheless important to consider the potential for enhanced recognition or cross-reactivity on a case-by-case basis. Significantly greater total percent reactive cells compared to WT TCR (significantly less nonreactive percentage) is denoted * P < 0.05, ** P < 0.001. a Averages of 3 independent experiments using 3 PBL donors (n = 9). b Moderate affinity APL. c Low-affinity APL. 
TA B L E 2
Percentages of IFN-producing and/or degranulating CD8 + T cells expressing chain pairing enhancing modified TCRs after stimulation with HCV APLs
